Abstract
The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications to the use of this drug.
Keywords: HCQ, diabetes mellitus, COVID-19, T2DM, vaccine, pandemic, SARS-CoV-2.
Infectious Disorders - Drug Targets
Title:COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail
Volume: 21 Issue: 5
Author(s): Rimesh Pal, Manoj K. Bhasin and Sanjay K. Bhadada*
Affiliation:
- Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012,India
Keywords: HCQ, diabetes mellitus, COVID-19, T2DM, vaccine, pandemic, SARS-CoV-2.
Abstract: The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications to the use of this drug.
Export Options
About this article
Cite this article as:
Pal Rimesh , Bhasin K. Manoj and Bhadada K. Sanjay *, COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail, Infectious Disorders - Drug Targets 2021; 21 (5) : e270421186842 . https://dx.doi.org/10.2174/1871526520666201013160803
DOI https://dx.doi.org/10.2174/1871526520666201013160803 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Biomarkers of Oxidative Stress in the Assessment of Enantioselective Toxicity of Chiral Pesticides
Current Protein & Peptide Science Diabetes Mellitus and Acute Coronary Syndrome: A Lethal Combination Requiring Better Therapeutic Strategies
Current Vascular Pharmacology miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’
Current Drug Targets Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Functional Food: Product Development and Health Benefits
Recent Patents on Engineering Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Study of HLA Class II and Autoimmune Diabetes
Current Molecular Medicine A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Suppression of TLR Signaling by Targeting TIR domain-Containing Proteins
Current Protein & Peptide Science Focus on the Correlations between Alzheimer’s Disease and Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Structure-based Design on Anticancer Drug Discovery
Current Topics in Medicinal Chemistry The Development of Preventives and Therapeutics for Alzheimers Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as Well as Destabilize Preformed fAβ
Current Pharmaceutical Design Cardioprotective Properties of HDL: Structural and Functional Considerations
Current Medicinal Chemistry Platelet Ca2+ATPases: Identification and Regulation in Hypertension
Current Hypertension Reviews Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) Bioartificial Pancreas: Drug Delivery through Islet Microencapsulation to Treat Diabetes
Recent Patents on Biomedical Engineering (Discontinued)